Envisioning a Healthy Future
Celgene's Five Pillars of Responsibility

**PATIENTS & COMMUNITIES**
Celgene provides support that makes a positive impact on patients, communities and the world.

**COMMITMENT TO SAFETY**
Pioneering the standard for patient and employee safety.

**GOVERNANCE**
Proactively implementing responsible business principles and practices in support of corporate governance.

**GLOBAL HEALTH**
Delivering our promise to put patients first through the pursuit of innovative solutions to healthcare challenges in low-income settings.

**ENVIRONMENTAL SUSTAINABILITY**
Promoting environmentally responsible, safe and sustainable business practices in our day-to-day operations.

For more information, visit Celgene’s Responsibility web site at [http://www.celgenecr.com](http://www.celgenecr.com).
A Passion for Helping Patients Live Longer, Better, Healthier Lives

At Celgene, we are committed to improving the lives of patients and advancing the course of human health in the interest of global prosperity and progress. We promise to always put our patients first, by ensuring that patients within Celgene’s global market reach have safe, well controlled access to life-enhancing therapies and by improving patient care globally through education, innovation and bold pursuits in science. We bring that same desire to contribute to society’s health and development to a broader perspective by informing stakeholders of our efforts with the release of our inaugural Celgene Responsibility Report.

We continue to establish new relationships that provide us with the opportunity to deepen our pipeline while at the same time broadening our scientific approach for new innovative solutions to treat serious and debilitating diseases. We are emerging as a leader in the biopharmaceutical sector enabled by a pipeline of sustainable innovation. Currently, over 50,000 patients worldwide access our novel therapies through more than 400 clinical studies. Our research applies transformational science and translational medicine in the areas of immunomodulation, epigenetic hypomethylators and histone deacetylase inhibitors, cellular and vaccine-based therapies, kinase inhibitors and cancer metabolism.

As a part of our vision for the future, Celgene is committed to conducting business in a safe, sound and sustainable manner. We respect our environment and conduct our business every day based on integrity, ethics, sound decision making and behaviors that reflect our values.

Celgene’s environmental programs strive for continuous improvement. Our facilities are designed and operated incorporating the principles of environmental stewardship. We report our greenhouse gas emissions, water management and climate change strategies through the Carbon Disclosure Project. We are improving energy efficiency, and will continue to work toward improvements and emission reductions going forward.

At Celgene, there is no higher priority than to fulfill our promise of delivering critical therapies to patients in need around the world. We have strengthened our commitment to maintaining our industry-leading patient assistance and safety programs that ensure, to the maximum extent possible, that those who can benefit from our therapies have the opportunity to receive them safely.

Our corporate culture reflects our mission to improve the lives of patients worldwide. We are an organization that cares deeply about patients and works tirelessly to provide them with new solutions in medicine. The more innovative therapies we bring to the market, the better the outcomes for patients, which in turn creates greater progress and prosperity both for the economy and society.

At Celgene, we are constantly on the move—growing, innovating, learning and evolving every day. This is an exciting and important time to be at Celgene. We have never been more optimistic about what we can achieve.

Robert J. Hugin
Chairman and Chief Executive Officer
Scope of this Report

Celgene is a pharmaceutical company dedicated to improving the patients’ lives around the world. We are committed to transparency with stakeholders and have chosen to follow the Global Reporting Initiative (GRI) guidelines in our first Celgene Responsibility Report. We plan to report our sustainability programs and achievements annually. We selected GRI indicators that apply to our business in a meaningful and challenging way and represent areas where we have an effect on the world. A list of the GRI indicators is provided at the end of this report. For a full explanation of the GRI guidelines, visit http://www.globalreporting.org.

For our inaugural report, the boundary encompasses the six sites included in our 2012 Carbon Disclosure Project response, as follows:

- Summit, New Jersey (Celgene Corporate Headquarters)
- Boudry, Switzerland (Celgene International Headquarters)
- Warren, New Jersey
- Cedar Knolls, New Jersey
- San Diego, California
- Phoenix, Arizona

Our reporting boundaries are based on equity share, where Celgene owns either the facility or significant carbon emitting equipment, and where data are available to support a proper and concise inventory. No partially owned subsidiaries or operations exist, and no operations exist for which Celgene has control but not ownership. Facilities and sources that are outside the selected boundary include leased vehicles and leased facilities (in particular, leased laboratory, warehouse and office space where Celgene does not own significant energy-consuming equipment or direct emission sources). Our future reports will be more comprehensive as our data collection and organizational boundary expands to sites and operations with notable impacts.

This Celgene Responsibility Report focuses on activities and performance during the 2011 calendar year. Historical data are included as appropriate and available. Plans for 2012 and beyond are provided, where applicable, to illustrate our approach to integrating programs that deal with sustainability across our global company. Monetary values provided throughout the report are in U.S. dollars.

1 Celgene owned a facility in Elk Grove Village, Illinois, during 2011 that is excluded from the reporting boundaries as a result of its recent acquisition and subsequent divestiture in 2012.
Contents

Our Global Company 6
  Activities, Products and Markets Overview 7
  Organizational Structure 9
  Governance and Leadership 9
  Our Stakeholders 11
  Our Workforce 12

Improving Human Health 14
  Corporate Giving 14
  Celgene Patient Support and Advocacy 15
  Products 17

Supporting Environmental Health 19
  Energy 20
  Carbon Footprint 22
  Environmental Compliance 23
  Water 24

Sustaining Economic Growth 25
  Company Performance 25
  Innovation in Research and Development 25

Global Reporting Indicator Index 26

Our Promise

Put patients first by ensuring that patients within Celgene’s global market reach have safe, well-controlled access to life-enhancing therapies and improve patient care globally through education, innovation, and bold pursuits in science.

“At Celgene, there is no higher priority than to fulfill our promise of delivering critical therapies to patients in need around the world.”

- Robert J. Hugin, Chairman and Chief Executive Officer
  Summit, New Jersey, U.S.
Our Global Company

For more than 25 years, Celgene Corporation has worked to improve the lives of patients around the world. Our approximately 4,500 global employees are engaged in the discovery, development and commercialization of therapies for treating cancer and immune-inflammatory diseases.

Celgene’s commitment to patients is reflected in our growing portfolio of innovative therapies and patient services, including REVLIMID®, THALOMID®, VIDAZA®, ABRAXANE®, ISTODAX® and LifebankUSA®. Currently, our therapies are available in more than 70 countries.

Through innovative research and development, our employees are advancing progress in several scientific areas that may deliver next-generation therapies. Our research targets areas such as intracellular signaling pathways in cancer and immune cells, immunomodulation in cancer and autoimmune diseases and therapeutic application of cell therapies.

Celgene is a publicly owned company that is traded on the NASDAQ stock market. Annual revenues for 2011 were $4.8 billion. Over the years, Celgene has expanded into new clinical fields and expanded our development of disease-altering therapies focused on delivering quality outcomes for better healthcare.

Global Presence

Celgene Corporation is headquartered in Summit, New Jersey, U.S., with our international headquarters based in Boudry, Switzerland. Although our core manufacturing, operations and research facilities are in North America and Europe, recent expansions have broadened our firm’s presence throughout Asia, Latin America and Australia.

The map shows the locations where Celgene operates office, manufacturing and research centers, and highlights the six facilities included in the scope of this Celgene Responsibility Report.
Activities, Products and Markets Overview

Our mission is to build a major global biopharmaceutical company by discovering, developing and bringing to patients innovative new therapies to treat cancer and other severe conditions. Our major market segments and service areas include:

- **Celgene Hematology** is the foundation on which our company was built. From our earliest efforts with thalidomide in myeloma to ongoing clinical studies in multiple diseases, our therapies are transforming the landscape of the treatment of blood cancers.

- **Celgene Oncology** has come about from an expanded view of indications in which we believe we can make a significant contribution. In particular, solid tumor cancers are a natural extension of the success we have achieved in hematology. Our innovative compounds are showing promise in a range of tumor types. Our principal therapy combines a traditional taxane with human albumin through a unique nanotechnology-based formulation process. The resulting product delivers more of the drug to its intended destination, while simultaneously minimizing solvent-related safety concerns.

- **Celgene Inflammation and Immunology** holds the potential to help a large group of patients outside of our core cancer discipline, those living with debilitating immune-related and inflammatory diseases like psoriasis, arthritic conditions, Crohn’s disease and more. Built upon the ongoing research of scientists in both Celgene and Celgene Cellular Therapeutic laboratories, I&I now features an emerging pipeline of innovative oral immunomodulatory compounds, kinase inhibitors and placenta-derived cellular therapies. Long a part of the company’s pipeline, these therapies are rapidly moving into late-stage clinical trials where they are addressing significant unmet needs in serious disease areas.

- **Celgene Cellular Therapeutics (CCT)**, our cellular therapies research division, focuses on stem cells derived from human placentas and umbilical cord blood. Stem cell-based therapies represent an important new option in the treatment of currently untreatable diseases.

OUR GLOBAL COMPANY

Our culture is a unique system that allows us to do our best work, deliver exceptional results, achieve our purpose and respect our environment.

PASSION FOR THE PATIENT
We share a belief that what we do matters to the world – that it is essential to the advancement of healthcare. And that how we do it is what sets us apart from those who have come before us, as well as those we will meet in the future.

COURAGE TO FACE OUR CHALLENGES AND THE UNKNOWN
We will boldly face the challenges of the past and the uncertainties of the future. We embrace the unknown, pioneering new science and new ways of doing business. Our willingness to challenge the status quo and take on risk is what enables us to create new standards in medicine, and the broader world of human health.

TRUST IN OUR WORDS AND ACTIONS
We assume the best in each other – in terms of capability and intention – and we treat each other with dignity and respect as we work together to always do what’s best for Celgene. We value each individual for the integrity they bring to their work and their relationships, both internal and external.

EXCELLENCE IN DELIVERING EXCEPTIONAL RESULTS
We hold our work to the highest of standards – quality, scientific, and ethical. We also hold each other to equally high standards in the way we work, encouraging creativity and simplicity in problem-solving, transparency in communicating, and results that are data-driven.

WE ASSUME THE BEST
We start from a place of inquiry, honoring diverse points of view, seeking to understand each other and giving everyone a chance to be heard.

WE DEBATE OPENLY, HONESTLY, AND COMPLETELY
We share our views or disagreements fully in every conversation to encourage the best ideas to emerge.

WE MAKE DECISIONS OBJECTIVELY AND TRANSPARENTLY
We are clear about our roles, include the right people in the conversation, consider the facts, and share our reasoning.

WE ALIGN AND FOLLOW THROUGH
We carry the decisions we make as a team, and agree to a process for changing and communicating them.

A GLOBAL MINDSET “Big company success, small company feel!”
We engage our global colleagues in the discussions and decisions that shape who we are and how we believe – within Celgene and throughout the world. We honor the decisions that affect our daily work, and respect the process for changing them.

CLEAR OBJECTIVES “We are focused on the right thing”
We prioritize our work according to the stated vision and goals of the company. We take ownership of our role in contributing to the success of Celgene – adjusting timelines, budgets, and people – in response to official changes in our corporate priorities.

AN ALIGNED ORGANIZATION “We are in this together”
We coordinate our resources and make trade-offs in ways that benefit the whole. We understand that our decisions and our work have an impact on others and we act accordingly, sharing responsibility for outcomes and avoiding the blame-game. We prioritize processes that allow us the freedom to create and the ability to solve problems together.

AN ENGAGED WORKFORCE “Everybody matters”
We honor the contribution that each person makes – on the front lines, at the bench, or in the back office. We encourage each other to take on new responsibilities and explore new areas of growth. We respect that people have full lives and do what we can to create work-life balance.

GOOD COMMUNICATION “We are all in the know”
We are accessible to each other and communicate mindfully, respecting cultural norms of tone, time zone, and responsiveness. We ensure that the information people need to do their job is available and accessible.

Our Values
The qualities we look for in our people

Passion
We are developing our Sustainability and Environmental Policies to support our commitment to helping the planet as we help patients.

Courage to face our challenges and the unknown
Climate change and other uncertainties face the world and our business. Our Risk Management Policy under development and Carbon Disclosure Project (CDP) reporting explain what we are doing as we all look towards the future.

Trust in our words and actions
We must act in concert. We build and leverage relationships within the communities where we work.

Excellence in delivering exceptional results
Our capabilities and processes are managed for resource efficiency and a state of the art performance.

We assume the best
We honor diverse points of view from our stakeholders, patients, investors, and communities.

We debate openly, honestly, and completely
As we assess what initiatives to undertake, we collaborate with employees and other stakeholders about our impacts and opportunities.

We make decisions objectively and transparently
With our inaugural responsibility report, we pledge to objectively and transparently communicate the results of our sustainability initiatives.

We align and follow through
By consistently measuring our year-over-year, we assess our progress against our environmental objectives.

A global mindset
We engage with partners who can help us reach patients around the world.

Clear objectives
We create a clear set of goals for measuring and improving our environmental performance.

An aligned organization
Responsibility – which we define as caring for human health and environmental health while sustaining our business – aligns with our core mission of patient care.

An engaged workforce
Everyone can contribute to responsibility through activities like recycling, volunteerism, and resource-conserving innovations.

Good communication
We engage with employees, stakeholders, investors, and the communities where we work to improve upon our responsibility initiatives.

Changing the course of human health through bold pursuits in science, and a promise to always put patients first.
Celgene’s Award-Winning Performance

Celgene’s innovative approach has been recognized with two awards: a place on the 2011 Forbes Most Innovative Companies list at number 12 and the 2011 Edison Patent Award from the Research and Development Council of New Jersey. Celgene also received Winning Company recognition from the 2020 Women on Boards initiative, a national campaign to increase the percentage of women on U.S. company boards to 20 percent or greater by the year 2020. Celgene’s Board of Directors was recognized because it already exceeds the 20 percent goal.

Organizational Structure

Our organization encompasses two major businesses, namely Hematology/Oncology and Immunology/Inflammation. Each business is supported by various functions, including but not limited to Celgene patient support, medical affairs, research and development, regulatory affairs and other shared corporate functions.

Governance and Leadership

Celgene establishes and regularly reviews policies and practices that support corporate governance and transparency in reporting. Celgene’s responsibility program is governed by diverse corporate policies across our organization from ethics and safety to risk management. We are planning to develop our Sustainability Policy in 2012. It will become the overarching document that links our commitment to patients with our commitment to the environment and a healthy future. Two additional policies under development are our Environmental Opportunity and Risk Policy, and our Environmental Policy.

Our vision is to build a major global biopharmaceutical company by discovering, developing and bringing to patients innovative new therapies to treat cancer and other severe conditions.

For more information about Celgene’s Board of Directors and governance, please visit http://ir.celgene.com/phoenix.zhtml?c=111960&p=irol-govHighlights.
Thank you for reading our first Celgene Responsibility Report, and for joining Celgene and our department in creating a sustainable vision for our company’s future. It is my privilege to work alongside the many talented people of Celgene who bring health to so many individual lives, and my honor to help us all make the world at large a healthier place.

Our engineering department is entrusted with the responsibility to make our facilities function with resource efficiency at the forefront. We are currently constructing a new facility in San Diego, CA, to LEED™ standards, and have implemented projects at a number of other facilities to reduce our environmental footprint.

With the endorsement and support of our corporate leaders, we have established programs to improve energy efficiency, reduce waste generation and maintain water quality. Some of the steps that we have taken include projects that we can directly measure, such as upgrading building management systems and controls. Other important programs include providing a shuttle for employees who choose to take the train to work or use other alternative transportation. In 2011, Celgene began supporting employees who use electric vehicles by installing charging stations at our corporate headquarters.

Along with innovation and science, improving our facilities and managing our environmental footprint is an important part of putting patients first and doing our best to ensure a healthy and sustainable future.

Doug Mac Gorman
Director of Engineering, Construction and Carbon Management
Our Stakeholders

Celgene is committed to improving the lives of patients by discovering, developing and bringing to patients innovative new therapies to treat cancer and other severe conditions. This work is accomplished by maintaining a commitment to and dialogue with our key stakeholders.

Our network of stakeholders includes patients, employees, healthcare providers, advocates, universities and research institutions, shareholders, governments, communities, suppliers and many others.
Our Workforce

By the end of 2011, Celgene had approximately 4,500 employees worldwide with a diverse range of roles and responsibilities and a focused goal of achieving optimal yields and performance for our patients and for the company. The workforce charts in this section apply only to the 1,521 employees represented in the six facilities within the reporting scope and not to the entire employee population of our company.

Celgene is dedicated to enhancing professional development of our personnel through commitments for reconciliation, diversity, training, safety and security. These benefits apply to the company and subsidiaries, creating a team that delivers and achieves professional excellence.

Our employees are a diverse group of talented people, including Ph.D. bench scientists, doctors, manufacturing engineers, information technology professionals, clinical research physicians, laboratory technicians, marketing professionals, sales representatives, regulatory experts, finance personnel, clinical coordinators, human resource managers, nurses and pharmacists.

Celgene employs people with specialized skills, and we have capitalized on the increased availability of highly trained and qualified individuals. Our ongoing success in serving our patients enables us to continue to attract high-quality people at every level. Celgene is committed to the professional development of our employees, encouraging them to meet their own personal and professional goals, as well as the evolving needs of the patients we serve. Our guiding principles for employee development are at http://jobs.celgene.com/content/professional-development/.
Business Conduct and Ethics

We encourage respect and foster working environments where people can expand their professional experience and explore new areas of growth. Our policies honor the fundamental rights of our employees. Celgene’s *Code of Business Conduct and Ethics* reflects our commitment to a culture of honesty, integrity and accountability. Our employees are expected to apply the principles of the Code consistently. For more information, please visit the compliance and ethics section of Celgene’s responsibility web site at http://celgenecr.com/governance/compliance-ethics.

“Critical to delivering on Our Promise of improving the lives of patients worldwide is an energized, innovative and high-performing workforce that has the opportunity to grow, develop and make an impact.”

Philippe Van Holle, Senior Vice President
Global Human Resources

Safety and Wellness

We strive to provide a safe, healthy and environmentally responsible work environment for our employees and visitors to our facilities. Celgene monitors, tracks and routinely reports on the company’s health and safety performance, and continually reviews risks to better protect our people. The statistics in this section apply to the five U.S. facilities within the reporting scope and are collected in accordance with U.S. Occupational Safety and Health Administration guidelines. In 2011, Celgene recorded 5 lost workdays resulting from work-related injury or disease, a ratio of 0.42 lost days per 100 employees. No occupational disease cases were reported and no work-related fatalities occurred in 2011. A total of 18 employees were injured in 2011, a ratio of 1.52 injuries per 100 employees. For more information, visit http://celgenecr.com/commitment-to-safety/employee-safety/.

### 2011 Safety Incidents: US Facilities

<table>
<thead>
<tr>
<th></th>
<th>Male</th>
<th>Female</th>
<th>Total</th>
</tr>
</thead>
<tbody>
<tr>
<td>Total Injuries</td>
<td>7</td>
<td>11</td>
<td>18</td>
</tr>
<tr>
<td>Incident Rate per 100 Employees</td>
<td>0.59</td>
<td>0.93</td>
<td>1.52</td>
</tr>
<tr>
<td>Total Lost Days</td>
<td>3</td>
<td>2</td>
<td>5</td>
</tr>
<tr>
<td>Total Lost Days Rate per 100 Employees</td>
<td>0.25</td>
<td>0.17</td>
<td>0.42</td>
</tr>
</tbody>
</table>

*“Days” refer to scheduled work days. First-aid level injuries are excluded.*
Improving Human Health

Corporate Giving

Celgene provides grants and sponsorships to organizations that make a positive impact on patients in numerous communities across the world. We are committed to improving the lives of patients worldwide and focus our charitable giving in areas where we can achieve the greatest outcome.

Our corporate giving includes various donations for healthcare and science-related educational programs and patient education activities. We also provide sponsorship and funding toward select community activities in local areas where we do business. In recent years, Celgene has partnered with global organizations on initiatives designed to improve the lives of patients with serious diseases, foster early science, math and engineering education, and help build strong communities where we live and work.

In 2011, Celgene donated $46.7 million to charitable causes around the world. In the U.S., Celgene also contributes tens of millions of dollars in unrestricted donations to charitable foundations that administer support programs to pay or refund the treatment costs of patients without adequate insurance coverage.

Coupled with support for medical initiatives and donations to third-party co-pay assistance foundations, we have built a solid foundation of giving tied to Our Promise to patients.

Areas of Giving

Celgene provides grants that make a positive impact on the patients we serve, our communities and our world, today and for years to come. We are committed to improving the lives of patients worldwide and focus our giving in areas where we can make the greatest impact.

Our giving is focused in three primary areas:

- Independent Medical Education
- Patient Focused Advocacy Partnerships
- Philanthropic Charitable Support

Celgene Patient Support and Advocacy

Celgene Patient Support provides a dedicated, central point of contact for patients and healthcare professionals who use Celgene products. Celgene Patient Support is a free service that helps patients and healthcare professionals navigate the challenges of reimbursement while providing information about co-pay assistance and access to Celgene therapies.

Celgene Patient Support specialists can work with patients to:
- Explain benefits
- Facilitate prior authorization
- Assist with appeal support after insurance denials
- Help understand Medicare coverage
- Find co-pay foundations to help with patient out-of-pocket costs
- Follow up on prescription status
- Help patients apply for the Celgene free medication program
- Guide patients through restricted distribution programs for Celgene products

Celgene Patient Advocacy collaborates with independent patient organizations that support and advocate on behalf of patients and their families. We work with these groups to strengthen their support for patients from diagnosis to chronic treatment and end-of-life care. These collaborations are critical to achieving our common mission of improving the lives of the people we serve. For more information, please visit http://www.celgene.com/patient-support/celgene-support-program-home.aspx.

“‘The Celgene Patient Advocacy Team is dedicated to building alliances across the patient and professional communities to accelerate the development of solutions that will meet the needs of patients and families living with debilitating and life-threatening diseases.’”

Joel W. Beetsch, Vice President of Patient Advocacy

More than 20,000 patients have received assistance from Celgene Patient Support since 2007.
Celgene Global Health

At Celgene, we believe patients should have the opportunity, regardless of their location or financial resources, to benefit from advances in prevention, diagnosis and treatment of disease.

Celgene Global Health collaborates with partners around the world to find solutions for healthcare challenges in the developing world. Celgene has more than 400,000 compounds in our library across multiple platforms, including immunomodulation, cell signaling inhibition and cellular/tissue therapies. These platforms have potential applications in diseases of the developing world, such as tuberculosis, malaria, leishmaniasis, trypanosomiasis, lymphatic filariasis and others.

Over the past 10 years, Celgene has provided more than $550 million in medication at no cost to patients.

Celgene Global Health collaborates with product development partners, academic institutions, nongovernmental organizations, public/private funding organizations and other pharmaceutical organizations to evaluate how our therapies may aid in treating often overlooked diseases of the developing world. For more information, visit http://celgene.com/global-health/.

“At Celgene, our unique science and transformational therapies are turning once rapidly fatal and incurable diseases into more long-term manageable conditions, enabling patients to have longer and more productive lives. We partner with local medical experts and health systems in the developing world to identify best practices for expanding access to safe and effective medicines.”

JERRY ZELDIS,
Chief Medical Officer and CEO of Celgene Global Health

JUAN ZHUANG
Nantong City, Jiangsu Province, China
Metastatic Breast Cancer Patient
### Products

Today, our portfolio of approved drugs, now encompassing lenalidomide, thalidomide, azacitidine, romidepsin and nab® paclitaxel, provides life-changing benefits to patients in more than 70 countries.

In one area of disease, blood cancers, clinical data are showing us that now, more than ever, we are increasing survival rates for patients and lessening the financial burden on the healthcare system. In fact, Brian G.M. Durie, M.D., co-founder and chairman of the International Myeloma Foundation said, “With the novel therapies we’re seeing a quantum leap in two-year survival from 50 percent to now 93 percent, which is just 3 percent short of what a healthy person of a comparable age could expect.”

Additionally, our therapies are addressing solid tumor diseases for which there have been few successful therapeutic options. Through researching powerful mechanisms such as modifying the body’s immune response, or unique delivery systems that turn cancer cells’ own survival mechanisms against them, we strive to make significant improvement in patients’ outcomes. Our lead candidate in immunology and inflammation, apremilast, like many of our other therapies, is an oral agent that patients can take at home, helping to preserve their quality of life.

Celgene Cellular Therapeutics (CCT), our wholly owned subsidiary focused on the development of stem cell therapies, is pioneering state-of-the-art research in placenta-derived cells, including the first clinical use in this area. Having developed proprietary technologies for collecting, processing and storing placental stem cells, CCT is now evaluating the potential of cellular therapies in cancer as well as in a number of other autoimmune, cardiovascular, neurological, inflammatory and degenerative diseases.

For more information about our products, please visit [http://www.celgene.com/products/revlimid-thalomid-home.aspx](http://www.celgene.com/products/revlimid-thalomid-home.aspx).


### Clinical Trials

Hundreds of clinical trials are underway at major medical centers around the world, evaluating compounds developed at Celgene. Clinical trials are a critical part of our research and development pipeline, ensuring that the life-saving treatments that reach patients are both safe and effective. Our research and development team works in collaboration with our patient safety team to ensure that patients who participate are involved in safe, well-planned studies. To access a current list of Celgene’s clinical trials, please visit [http://celgenecr.com/patients-and-communities/clinical-trials-2/](http://celgenecr.com/patients-and-communities/clinical-trials-2/).
Product Safety and Patient Education

The safety of the patients we serve is of paramount importance. Our products are marketed and distributed with thorough labeling and product information. Celgene develops labeling and informational material in compliance with regulatory bodies such as the U.S. Food and Drug Administration and the European Medicines Agency. All drugs currently marketed by Celgene are required to include labeling approved by the applicable regulatory bodies.

The most critical part of our labeling efforts is conveying how to safely access our therapies, including:

- Drug description and information
- Drug clinical pharmacology
- Functions and mechanisms
- Dosage quantity
- Proper administration of drug
- Warnings and precautions
- Adverse reaction information
- Drug interactions
- Use in specific patient populations
- Supply of drug and proper storage

In addition, detailed information is provided regarding the results and evaluations of the drugs during clinical trials. This information explains how the clinical trial was organized, the types of dosage and administration used and the results of the trial. This information reflects the most important studies that resulted in approval of the drug for marketing and distribution for patient use.

Beyond labeling, Celgene Patient Support provides an ongoing source of information and advocacy for our patients. For more information, please visit http://celgenecr.com/commitment-to-safety/.

JAMES FERRELL
Enumclaw, WA
Peripheral T-cell Lymphoma Patient
Celgene seeks to improve our understanding of the company’s environmental impacts by investigating and incorporating technologies to reduce our global footprint. We seek to increase energy efficiency, decrease water consumption and limit greenhouse gas emissions in facility operations. A prime example of our environmental efforts is the Celgene International Headquarters in Boudry, Switzerland, a state-of-the-art facility that was awarded Minergie® status for achieving superior energy efficiency performance.

Each year, we report our greenhouse gas emissions, water management and climate change strategies through the Carbon Disclosure Project. The disclosure of this information is helping our company prioritize efforts and projects for reducing our environmental impact and continuing our commitment to sustainability. Celgene strives to address the following environmental aspects:

- Regulatory compliance with environmental laws
- Energy and fuel conservation
- Employee awareness
- Performance improvement
- Pollution prevention and waste minimization
- Water conservation
- Supply chain impacts
- Reporting and disclosure

Our environmental sustainability management approach is to incorporate best practices and programs related to energy, water, waste, transportation and supply chain operations within our company. We have reduced our energy consumption and invested in clean and renewable technologies, thus reducing our carbon footprint in 2011. We have improved water conservation and implemented water reuse and recycling programs. For more information, please visit [http://celgene.com/environment-sustainability/](http://celgene.com/environment-sustainability/).
Energy

Celgene is committed to reducing our overall energy consumption in facilities while integrating energy derived from renewable and sustainable sources. As we continue to build a foundation of effective carbon management at Celgene, our initiatives for energy conservation and efficiency reflect our drive toward environmental sustainability. Energy performance reporting is based on published and verified protocols. Our data collection, review and reporting process is continuously refined and augmented to incorporate new energy reduction and sustainability projects.

Our direct and indirect energy use decreased from 2010 to 2011. Direct energy is energy generated onsite from fuel, such as burning wood pellets in boilers or using gasoline in vehicles. Indirect energy is energy produced externally that is consumed onsite, such as electricity from a power plant.

Celgene already has begun to invest in and develop energy-efficient strategies within our operations. Celgene’s participation in New Jersey Clean Energy’s Pay for Performance Program has included the following enhancements to our energy infrastructure (anticipated to be fully completed in 2012):

- Boiler replacement and optimization of system, including using natural gas in place of fuel oil
- Upgrading the building management system and its direct digital controls
- Replacing existing motors with more efficient motors
- Optimizing the chilled water system
- Various upgrades and replacements to the lighting systems

These improvements will reduce consumption of both natural gas and electricity over an estimated 15 to 25 years of project lifetime while creating an economic payback period of less than 5 years.
Saving Energy in Switzerland

Celgene International Sàrl (our Boudry, Switzerland facility) has committed to reducing carbon emissions and optimizing energy efficiency. The facility is a member of the Swiss Private Sector Energy Agency’s Voluntary Climate Protection Program and the Swiss Federal Government audits their target agreements for energy and carbon emission reductions. Ten measures have been defined for the next 3 years, and those implemented in 2011 included:

- Purchasing electricity from renewable energy sources (4 gigajoules [GJ] were purchased in 2011)
- Shutting down the heating system in the technical basement
- Reducing heating in corridors and staircases
- Reducing cooling measures in uninterruptible power supply rooms
- Reducing hot water flow rate
- Optimizing the temperature in data centers
Carbon Footprint

Celgene’s carbon footprint is attributed to sources such as consumption of electricity, stationary combustion (boilers, generators), vehicles, refrigeration, fire suppression and laboratory chemicals. Celgene began assessing greenhouse gas emissions during 2008 in conjunction with our first Investor Carbon Disclosure Project submittal completed in 2009. Methodologies conform to the Climate Registry’s General Reporting Protocol and the World Resource Institute’s Greenhouse Gas Protocol.

Currently, Celgene assess and reports emissions for Scope 1 (stationary combustion, mobile combustion, refrigeration, fire suppression and laboratory chemicals) and Scope 2 (purchased electricity). In the future, Celgene plans to evaluate Scope 3 emissions, such as from business travel, solid waste disposal and employee commuting.

We have realized carbon reductions in our operations, as measured in carbon dioxide equivalent (CO$_2$e), through reduced energy consumption and use of energy sources with lower carbon emissions.

“Celgene continues to advance multiple initiatives to reduce our carbon footprint. Investing in solar panels, electric vehicle charging stations and more means we take the environment seriously, even when the impacts are external to our operations.”

Vince Barilla
Executive Director of Facilities
Energy and Carbon Reductions: Dual Benefits

Celgene actively seeks ways to save energy and reduce carbon emissions while meeting business needs. Reducing the need for fuel oil and natural gas inherently reduces energy use and carbon emissions. Taking it a step further, replacing fuel oil with natural gas offers additional carbon savings. At LifebankUSA®, the critical need for cold storage is met with energy-efficient compounds that do not contain ozone-depleting compounds nor emit greenhouse gases. Additional examples include:

- **Summit**: Fuel Oil #2 reduced (and nearly eliminated) by 142,000 GJ
- **Boudry**: Natural gas reduction by 1.13 million GJ
- **San Diego**: Natural gas reduction by 14,000 GJ

### GHG Emissions by Type

<table>
<thead>
<tr>
<th>Total GHG Emissions</th>
<th>Purchased Electricity GHG Emissions</th>
<th>Stationary Combustion GHG Emissions</th>
</tr>
</thead>
<tbody>
<tr>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
<td><img src="image" alt="Graph" /></td>
</tr>
</tbody>
</table>

Environmental Compliance

At Celgene, we are committed to conforming to the rigorous standards set forth by environmental rules and regulations. Our Environmental Health and Safety Department continuously audits our facilities, including manufacturing, office, and research and development facilities, for compliance. This management system audits air quality, material and chemical safety, and proper waste management in our operations.

In 2011, Celgene did not receive any compliance complaints, violations or sanctions from the U.S. Environmental Protection Agency concerning air quality or resource management. Additionally, no significant spills were associated with any type of fuel, waste or chemical used at our facilities. Celgene continues to adhere to federal, state and local regulations concerning environmental compliance and has numerous management procedures in place should a situation arise concerning non-compliance.
Water

We understand water is a precious resource for our operations as well as in the global communities in which we do business. Water is used for a variety of purposes, especially in laboratory experimentation and final manufacturing of our products. Additional purposes include personnel consumption, facility cooling operations and cleaning and maintenance operations.

Celgene prepared and reported our 2011 baseline water inventory of the six facilities within the scope of this report for our 2012 Carbon Disclosure Project Water Disclosure submittal. Similar to our energy performance, our water data collection, review and reporting process is continuously refined and augmented to incorporate new water conservation and management projects. Celgene uses the World Business Council for Sustainable Development’s Global Water Tool to identify sites in water-stressed regions. We use this information to consider water-related risks and opportunities, and determine where our conservation and management efforts could have the greatest impact.

Celgene has invested in water conservation and management projects and strategies and we will continue to investigate and enhance our water performance at our facilities.

Water Conservation Improvements

Recent water conservation efforts include:

- **Summit**: Installed rain sensors on irrigation systems that automatically shut off the system when it rains, eliminating unnecessary water use.
- **Boudry**: Added a rainwater collection tank that provides water for use in toilets and landscape watering. Reduced the flow of hot water in every restroom.
- **San Diego**: Reclaimed municipal wastewater is used for landscaping.
- **Cedar Knolls**: Replaced all faucets with more efficient fixtures and models.

Water Withdrawn by Source (cubic meters per year)

<table>
<thead>
<tr>
<th>Source</th>
<th>Amount</th>
</tr>
</thead>
<tbody>
<tr>
<td>Municipal Water Supplies &amp; Utilities</td>
<td>228,480</td>
</tr>
<tr>
<td>Rainwater Collection</td>
<td>2,500</td>
</tr>
<tr>
<td>External Wastewater</td>
<td>29,560</td>
</tr>
<tr>
<td><strong>Total</strong></td>
<td><strong>260,540</strong></td>
</tr>
</tbody>
</table>
Innovation is key to improving quality of life, reducing healthcare costs, increasing productivity and driving economic growth. Celgene is committed to delivering innovative therapies that improve the lives of patients around the world.

Our growing investment in developing immunomodulatory agents and cell-signaling inhibitors, as well as in developing cellular and tissue therapeutics, will allow us to provide physicians and clinicians with a more comprehensive and integrated set of solutions for managing complex human disorders such as cancer and inflammatory diseases.

Company Performance

Celgene’s 2011 revenue was $4.8 billion. Our 2011 economic profile, shown above right, represents our revenues and expenses, including our financial contributions to non-profit organizations, research groups and miscellaneous entities. Charitable contributions are detailed in the Corporate Giving section.

Innovation in Research and Development

Celgene has a proven record of delivering better outcomes and better healthcare through innovation. Over the last 5 years, Celgene reinvested more than 30 percent of revenues in research and development—twice the industry average.

This commitment to research has enabled our company to build a broad and deep pipeline through our own efforts and as a part of several strategic collaborations with outside partners that may represent the next advances in treating blood and solid tumor cancers, as well as immune-inflammatory conditions. Many therapies are now in clinical development and under regulatory review in the U.S. and internationally.

Of the trends that will create a prosperous future, innovation will be among the most important. Only by nurturing this process will companies like Celgene be able to continue delivering the disease-altering therapies that are extending patients’ lives and discovering the next-generation compounds that will mark the progress of medicine.
Global Reporting Indicator Index

We use the Global Reporting Initiative (GRI) indicators for sustainability reporting because these indicators constitute a familiar, globally accepted standard. In some cases, we have adjusted our reporting approach to reflect a more accurate depiction of Celgene’s business model; but in all cases, we respond to the spirit of the indicator. Celgene conforms to GRI Level C reporting standards.

<table>
<thead>
<tr>
<th>Section</th>
<th>GRI Indicator</th>
<th>Description</th>
<th>Pages</th>
<th>Document Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Strategy &amp; Analysis</td>
<td>1.1</td>
<td>Statement from the most senior decision maker of the organization about the relevance of sustainability to the organization and its strategy</td>
<td>3</td>
<td>Letter from the Chief Executive Officer</td>
</tr>
<tr>
<td>Organizational Profile</td>
<td>2.1</td>
<td>Name of the organization</td>
<td>4, 6</td>
<td>Scope, Our Global Company</td>
</tr>
<tr>
<td></td>
<td>2.2</td>
<td>Primary brands, products and/or services</td>
<td>7</td>
<td>Activities, Products and Markets Overview</td>
</tr>
<tr>
<td></td>
<td>2.3</td>
<td>Operational structure including major divisions, operating companies, subsidiaries and joint ventures</td>
<td>9</td>
<td>Organizational Structure</td>
</tr>
<tr>
<td></td>
<td>2.4</td>
<td>Location of the organization’s headquarters</td>
<td>4, 6</td>
<td>Scope, Global Presence</td>
</tr>
<tr>
<td></td>
<td>2.5</td>
<td>Number and names of countries where the organization operates with either major operation or that are specifically relevant this report</td>
<td>6</td>
<td>Global Presence</td>
</tr>
<tr>
<td></td>
<td>2.6</td>
<td>Nature of ownership and legal form</td>
<td>6, 9</td>
<td>Our Global Company, Organizational Structure</td>
</tr>
<tr>
<td></td>
<td>2.7</td>
<td>Markets served</td>
<td>7</td>
<td>Activities, Products and Markets Overview</td>
</tr>
<tr>
<td></td>
<td>2.8</td>
<td>Scale of the organization</td>
<td>6</td>
<td>Our Global Company</td>
</tr>
<tr>
<td></td>
<td>2.9</td>
<td>Significant changes during the reporting period regarding size, structure, or ownership</td>
<td>6</td>
<td>Our Global Company</td>
</tr>
<tr>
<td></td>
<td>2.10</td>
<td>Awards received in the reporting period</td>
<td>7</td>
<td>Activities, Products and Markets Overview</td>
</tr>
<tr>
<td>Report Parameters</td>
<td>3.1</td>
<td>Reporting period for the information provided</td>
<td>4</td>
<td>Scope, Reporting Statistics</td>
</tr>
<tr>
<td></td>
<td>3.2</td>
<td>Date of most recent previous report</td>
<td>First Report</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>3.3</td>
<td>Reporting cycle</td>
<td>4</td>
<td>Scope, Reporting Statistics</td>
</tr>
<tr>
<td></td>
<td>3.4</td>
<td>Contact point for questions regarding the report or its content</td>
<td>4</td>
<td>Scope, Reporting Statistics</td>
</tr>
<tr>
<td></td>
<td>3.5</td>
<td>Process for defining report content</td>
<td>4</td>
<td>Scope</td>
</tr>
<tr>
<td></td>
<td>3.6</td>
<td>Boundary of the report</td>
<td>4</td>
<td>Scope</td>
</tr>
<tr>
<td></td>
<td>3.7</td>
<td>Specific limitations on the scope or boundary of the report</td>
<td>4</td>
<td>Scope</td>
</tr>
<tr>
<td></td>
<td>3.8</td>
<td>Basis for reporting on joint ventures, subsidiaries, leased facilities, outsourced operations and other entities</td>
<td>4</td>
<td>Scope</td>
</tr>
<tr>
<td></td>
<td>3.10</td>
<td>Explanation of the effect of any restatements of information provided in earlier reports and reasons for such restatements</td>
<td>First Report</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>3.11</td>
<td>Significant changes from previous reporting periods in the scope, boundary, or measurement methods applied in the report</td>
<td>First Report</td>
<td>Not applicable</td>
</tr>
<tr>
<td></td>
<td>3.12</td>
<td>Table identifying the location of the Standard Disclosures in the report</td>
<td>26</td>
<td>GRI Index</td>
</tr>
</tbody>
</table>

We use the Global Reporting Initiative (GRI) indicators for sustainability reporting because these indicators constitute a familiar, globally accepted standard. In some cases, we have adjusted our reporting approach to reflect a more accurate depiction of Celgene’s business model; but in all cases, we respond to the spirit of the indicator. Celgene conforms to GRI Level C reporting standards.
<table>
<thead>
<tr>
<th>Section</th>
<th>GRI Indicator</th>
<th>Description</th>
<th>Pages</th>
<th>Document Section</th>
</tr>
</thead>
<tbody>
<tr>
<td>Governance, Commitments and Engagement</td>
<td>4.1</td>
<td>Governance structure of the organization</td>
<td>9</td>
<td>Governance and Leadership</td>
</tr>
<tr>
<td></td>
<td>4.2</td>
<td>Indication of whether the Chair of the highest governance body is also an executive officer</td>
<td>9</td>
<td>Governance and Leadership</td>
</tr>
<tr>
<td></td>
<td>4.3</td>
<td>Members of the highest governance body that are independents and/or non-executive members for unitary board structure</td>
<td>9</td>
<td>Governance and Leadership</td>
</tr>
<tr>
<td></td>
<td>4.4</td>
<td>Mechanisms for shareholders and employees to provide recommendations or direction to the highest governance body</td>
<td>9</td>
<td>Governance and Leadership</td>
</tr>
<tr>
<td></td>
<td>4.14</td>
<td>List of stakeholder groups engaged by the organization</td>
<td>11</td>
<td>Our Stakeholders</td>
</tr>
<tr>
<td></td>
<td>4.15</td>
<td>Basis for identification and selection of stakeholders with whom to engage</td>
<td>11</td>
<td>Our Stakeholders</td>
</tr>
<tr>
<td>Economic Performance Indicators</td>
<td>EC1</td>
<td>Direct economic value generated and distributed</td>
<td>14, 25</td>
<td>Corporate Giving, Company Performance</td>
</tr>
<tr>
<td>Environmental Performance Indicators</td>
<td>EN3</td>
<td>Direct energy consumption</td>
<td>20</td>
<td>Energy</td>
</tr>
<tr>
<td></td>
<td>EN4</td>
<td>Indirect energy consumption</td>
<td>20</td>
<td>Energy</td>
</tr>
<tr>
<td></td>
<td>EN6</td>
<td>Initiatives to provide energy-efficient or renewable energy based products and services</td>
<td>20, 21, 23</td>
<td>Energy</td>
</tr>
<tr>
<td></td>
<td>EN8</td>
<td>Total water withdrawal</td>
<td>24</td>
<td>Water</td>
</tr>
<tr>
<td></td>
<td>EN16</td>
<td>Total direct and indirect greenhouse gas emissions</td>
<td>22, 23</td>
<td>Carbon Footprint</td>
</tr>
<tr>
<td></td>
<td>EN18</td>
<td>Initiatives to reduce greenhouse gas emissions and resulting reductions</td>
<td>22, 23</td>
<td>Carbon Footprint</td>
</tr>
<tr>
<td></td>
<td>EN23</td>
<td>Total number and volume of spills</td>
<td>23</td>
<td>Environmental Compliance</td>
</tr>
<tr>
<td></td>
<td>EN28</td>
<td>Monetary value of significant fines and total number of non-monetary sanctions for non compliance with environmental laws and regulations</td>
<td>23</td>
<td>Environmental Compliance</td>
</tr>
<tr>
<td>Social Performance Indicators: Labor Practices and Decent Work</td>
<td>LA1</td>
<td>Total workforce by employment type, employment contract and region</td>
<td>12</td>
<td>Our Workforce</td>
</tr>
<tr>
<td></td>
<td>LA7</td>
<td>Rates of injury, occupational diseases, lost days and absenteeism, and number of work related fatalities by region and by gender</td>
<td>13</td>
<td>Safety and Wellness</td>
</tr>
<tr>
<td>Social Performance Indicators: Product Responsibility</td>
<td>PR1</td>
<td>Life cycle stages in which health and safety impacts of products and services are assessed for improvement</td>
<td>17</td>
<td>Clinical Trials</td>
</tr>
<tr>
<td></td>
<td>PR3</td>
<td>Type of product and service information required by procedures, and percentage of significant products and services subject to such information requirements</td>
<td>18</td>
<td>Product Safety and Patient Education</td>
</tr>
</tbody>
</table>
CELGENE CORPORATE HEADQUARTERS
86 Morris Avenue
Summit, New Jersey 07901
(908) 673-9000

CELGENE INTERNATIONAL HEADQUARTERS
Route De Perreux 1
2017 Boudry
Switzerland

www.celgene.com